My current research interests include AAV immune tolerance induction (ITI) therapy for hemophilia A, the more common form of hemophilia, to develop AAV-ITI based therapies to treat autoimmune disease and food allergy, to delve into the mechanism of AAV-ITI, and to develop improved mouse models to study and prevent capsid-specific CD8 T cell elimination of AAV transduced hepatocytes.
I have successfully obtained competitive funding from the NIH, Bayer Hemophilia Awards Program, and Pfizer Aspire Hemophilia Awards to work on optimizing adeno-associated virus liver gene delivery in murine and canine hemophilia B animal disease models, to elucidate the mechanism of tolerance induction with pre-existing immunity, to model and minimize detrimental anti-vector immune responses, to define minimally effective vector doses, and to assess the risks of administering suboptimal vector doses.
Subject Areas:
